SM
MITO

Sabby Management’s Stealth BioTherapeutics Corp. ADS MITO Stock Holding History

Sabby Management’s Portfolio MITO Stock Details MITO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-301,575
Closed -$473K – 198
2021
Q1 		$473K Buy
+301,575
New +$518K 0.09% 114

Other funds holding MITO

IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
BBHC
Brown Brothers Harriman & Co New York $22.8B AUM 25.09% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
SBL
Sargent Bickham Lagudis Boulder, Colorado $1.22B AUM 14.94% 1-Year Est. Return
PAM
PVG Asset Management Golden, Colorado $173M AUM 64.51% 1-Year Est. Return

Sabby Management's MITO Position: Q2 2021 in Review

Sabby Management sold out of Stealth BioTherapeutics Corp. ADS (MITO) in Q2 2021, closing a stake of 301,575 shares — an estimated $473K sold.

Sabby Management first reported a position in MITO in Q1 2021 and held it in 1 quarter. The position peaked at $473K in Q1 2021. 12 funds tracked by Wall St. Rank hold MITO as of Q2 2021.

  • Sabby Management reported no remaining Stealth BioTherapeutics Corp. ADS position as of Q2 2021 after selling out during the quarter.
  • Sabby Management sold 301,575 Stealth BioTherapeutics Corp. ADS shares in Q2 2021, an estimated $473K.
  • Sabby Management first reported a position in Stealth BioTherapeutics Corp. ADS in Q1 2021 and held it in 1 quarter.
  • Sabby Management's Stealth BioTherapeutics Corp. ADS position peaked at $473K in Q1 2021.
  • 12 funds tracked by Wall St. Rank held Stealth BioTherapeutics Corp. ADS as of Q2 2021.

Based on Sabby Management's 13F filing for Q2 2021, filed 16 Aug 2021.